An ancillary biomarker study of Gio-Tag Japan.
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000043299
- Lead Sponsor
- HANSHIN Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 93
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with no residual specimens collected in the main study (Gio-tag Japan) Patients whose data was rejected in the main study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of T790M rate before and after treatment with afatinib.
- Secondary Outcome Measures
Name Time Method Correlation between T790M rate before treatment with afatinib and response rate, progression-free survival, and overall survival of afatinib. Correlation between the T790M rate before the treatment with afatinib and the transition rate to second-line treatment. Correlation between T790M rate before treatment with afatinib, and response rate and progression-free survival rate of second-line treatment.